Clinical

Clinical  ·  Weekly Digest - 26 December to 02 January 2026
Alphamab Oncology announces IND application for a Phase 3 clinical study of HER2 bispecific ADC subcutaneous co-formulation JSKN033 as first-line treatment of advanced cervical cancer was officially accepted by CDE

Weekly Digest – January 2026 Weekly Digest – January 2026 29 December 2025: Alphamab Oncology announces IND application for a Phase 3 clinical study of HER2 bispecific ADC subcutaneous co-formulation JSKN033 as first-line treatment of advanced cervical cancer was officially […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 26 December to 02 January 2026
Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world

Weekly Digest – January 2026 Weekly Digest – January 2026 26 December 2025: Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world Junshi Biosciences has recently registered a […]

by Sandhya Ramalingam

Continue Reading